Lyra Therapeutics (LYRA) Competitors $6.29 -0.04 (-0.63%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$6.59 +0.30 (+4.77%) As of 09/12/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYRA vs. WOK, NEPH, NMTC, MODD, TMDIF, ECOR, CLGN, POCI, RBOT, and STRRShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include WORK Medical Technology Group (WOK), Nephros (NEPH), NeuroOne Medical Technologies (NMTC), Modular Medical (MODD), Titan Medical (TMDIF), electroCore (ECOR), CollPlant Biotechnologies (CLGN), Precision Optics (POCI), Vicarious Surgical (RBOT), and Hudson Global (STRR). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. Its Competitors WORK Medical Technology Group Nephros NeuroOne Medical Technologies Modular Medical Titan Medical electroCore CollPlant Biotechnologies Precision Optics Vicarious Surgical Hudson Global Lyra Therapeutics (NASDAQ:LYRA) and WORK Medical Technology Group (NASDAQ:WOK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk. Is LYRA or WOK more profitable? WORK Medical Technology Group has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,043.64%. WORK Medical Technology Group's return on equity of 0.00% beat Lyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lyra Therapeutics-5,043.64% -404.56% -60.06% WORK Medical Technology Group N/A N/A N/A Does the media favor LYRA or WOK? In the previous week, WORK Medical Technology Group had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 2 mentions for WORK Medical Technology Group and 1 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 1.91 equaled WORK Medical Technology Group'saverage media sentiment score. Company Overall Sentiment Lyra Therapeutics Very Positive WORK Medical Technology Group Very Positive Which has better earnings & valuation, LYRA or WOK? WORK Medical Technology Group has higher revenue and earnings than Lyra Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyra Therapeutics$1.53M6.74-$93.43M-$29.01-0.22WORK Medical Technology Group$11.51M3.96-$3.49MN/AN/A Do institutionals and insiders have more ownership in LYRA or WOK? 95.6% of Lyra Therapeutics shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate LYRA or WOK? Lyra Therapeutics currently has a consensus price target of $100.00, indicating a potential upside of 1,489.83%. Given Lyra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Lyra Therapeutics is more favorable than WORK Medical Technology Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00WORK Medical Technology Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryWORK Medical Technology Group beats Lyra Therapeutics on 6 of the 11 factors compared between the two stocks. Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.41M$2.59B$5.87B$10.14BDividend YieldN/A56.51%5.68%4.59%P/E Ratio-0.2223.5374.5225.93Price / Sales6.74699.42549.78198.13Price / CashN/A171.1637.5660.44Price / Book0.715.3712.166.29Net Income-$93.43M$32.95M$3.28B$270.77M7 Day Performance-8.18%1.28%0.87%3.88%1 Month Performance-13.72%6.09%4.96%4.88%1 Year Performance-55.07%-2.15%60.74%26.01% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics3.5253 of 5 stars$6.29-0.6%$100.00+1,489.8%-51.6%$10.41M$1.53M-0.2250Positive NewsHigh Trading VolumeWOKWORK Medical Technology GroupN/A$0.78+0.3%N/A-84.5%$44.46M$11.51M0.00226News CoveragePositive NewsNEPHNephros3.2 of 5 stars$3.93+2.6%$5.50+39.9%+127.2%$40.60M$14.16M32.7530Short Interest ↓NMTCNeuroOne Medical Technologies2.6484 of 5 stars$0.85+7.2%$1.45+70.6%+7.2%$39.64M$3.45M-5.6720Analyst ForecastHigh Trading VolumeMODDModular Medical1.2564 of 5 stars$0.72+0.5%N/A-65.8%$39.59MN/A-1.4120News CoverageGap UpTMDIFTitan MedicalN/A$0.34+2.7%N/A+990.4%$38.38M$17.63M-0.2750Gap UpECORelectroCore2.0641 of 5 stars$4.92+0.6%$25.50+418.3%-19.0%$37.08M$25.18M-3.0450Gap DownCLGNCollPlant Biotechnologies3.077 of 5 stars$2.64-2.9%$11.50+335.4%-45.8%$34.59M$510K-2.3470Short Interest ↓Gap UpPOCIPrecision Optics0.8078 of 5 stars$4.47-0.2%N/A-16.0%$34.31M$17.63M-5.0280RBOTVicarious Surgical1.7047 of 5 stars$6.28+10.4%$7.00+11.5%+2.9%$33.74MN/A-0.62210Analyst UpgradeSTRRHudson Global1.0937 of 5 stars$9.63+2.0%$5.00-48.1%+130.2%$31.15M$137.86M-7.411,300Gap UpHigh Trading Volume Related Companies and Tools Related Companies WOK Competitors NEPH Competitors NMTC Competitors MODD Competitors TMDIF Competitors ECOR Competitors CLGN Competitors POCI Competitors RBOT Competitors STRR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYRA) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
